Table 3.
The evaluation of sleep disturbance profiles with PSQI between treatment-naïve and treatment-experienced patients with HCV.
|
Treatment-naïve
(n = 27) |
Treatment-experienced (n = 75) |
Mann-Whitney U test | Quade's test+ | ||||
|---|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | U | p-value | p-value | |
| Subjective sleep quality | 1.44 | 0.974 | 1.19 | 0.865 | 851 | 0.192 | - |
| Sleep latency | 1.44 | 1.086 | 1.17 | 1.083 | 865.5 | 0.246 | - |
| Sleep duration | 1.22 | 1.086 | 1.23 | 0.981 | 1,001.5 | 0.931 | - |
| Habitual sleep efficiency | 0.26 | 0.656 | 0.77 | 1.06 | 745.5 | 0.018* | 0.028* |
| Sleep disturbances | 1.26 | 0.656 | 1.12 | 0.434 | 903 | 0.268 | - |
| Use of sleeping medication | 0.63 | 1.214 | 0.73 | 1.245 | 960 | 0.605 | - |
| Daytime dysfunction | 0.26 | 0.526 | 0.31 | 0.636 | 1,001 | 0.905 | |
| Global PSQI score | 6.52 | 3.577 | 6.52 | 3.86 | 960 | 0.689 | - |
+
Quade's test (age, sex, hypertension, diabetes mellitus, hyperlipidemia were set as covariates).
HCV, hepatitis C virus; SD, standard deviation.
*
Indicates p-value < 0.05.